Personalized Medicine Enters the US Marketplace: KRAS, Anti-EGFR Monoclonal Antibodies, and Colon Cancer
- 1 November 2009
- journal article
- editorial
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 16 (6) , 477-479
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal CancerAmerican Journal of Therapeutics, 2009
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Clinicopathologic features of EML4-ALK mutant lung cancerJournal of Clinical Oncology, 2009
- Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory studyBMC Cancer, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- EML4-ALK Fusion Lung Cancer: A Rare Acquired EventNeoplasia, 2008
- Big Question, Small AnswerJournal of Thoracic Oncology, 2008
- Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With CetuximabJournal of Clinical Oncology, 2007
- Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody TherapiesCancer Research, 2007
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005